Vecuronium Bromide
Norcuron®
10/2/2005
Action: Vecuronium is a nondepolarizing
neuromuscular blocking agent. It is about
a third more potent than pancuronium.
Duration of neuromuscular blockade produced by
vecuronium is shorter than that of pancuronium. The time to onset of paralysis
decreases and
the duration of maximum effect increases with increasing vecuronium
doses.
The level of
paralysis must be monitored.
The use of a peripheral nerve stimulator is of benefit in assessing the
degree
of muscular relaxation.
Remember: Vecuronium
has no known effect on consciousness, pain threshold or cerebration.
Administration must be accompanied by
adequate
anesthesia or sedation.
Reversal:
Neuromuscular block is reversed by acetylcholinesterase
inhibitors such as neostigmine, edrophonium,
and pyridostigmine. There have been
no
reports of recurarization following
satisfactory
reversal of vecuronium induced
neuromuscular
blockade. Fast recovery is a finding consistent with its short
elimination
half-life.
Dose: The amount requires to
produce
ninety percent suppression of a muscle twitch. Initial 0.08 to 0.10 mg/kg produces first
depression of twitch in about one minute.
Maximum neuromuscular block in about 3-5
minutes.
After
stopping drug recovery of
the control twitch is about 25 to 40 minutes. After
injection
of an INTUBATING dose. The
distribution
half-life following a single i.v. dose
(range 0.025
to 0.280 mg/kg) is approximately 4 minutes. Elimination half-life over
this
same dosage range is approximately 65 to 75 minutes
If succinylcholine is used
prior to vecuronium, the
administration of vecuronium should be
delayed until
the patient starts recovering from succinylcholine-induced
neuromuscular blockade.
Long
Term Use: Rarely
use of
neuromuscular blocking drugs to facilitate mechanical ventilation in
ICU
settings may be associated with prolonged paralysis and/or skeletal
muscle
weakness. This is
noticed during attempts to wean. Immobilized
patients may develop disuse muscle
atrophy. The benefits-to-risk ratio of
neuromuscular blockade must be considered.
Reconstitution and stability: When
reconstituted with bacteriostatic water
for
injection, use within 5 days. When reconstituted with recommended
diluents, use
within 24 hours. Single dose vial. Discard
unused
portion. Reconstitute each vial with 10 mL of bacteriostatic
water for injection or 10 mL of compatible diluent
to
obtain a solution containing 1 mg/mL vecuronium
bromide. Compatible diluents include: 0.9%
sodium
chloride injection, USP, 5% dextrose
injection, USP, 5% dextrose and 0.9%
sodium chloride injection, USP, sterile
water for injection, USP
and lactated Ringer's injection, USP.
Monitor: Whenever the use
of vecuronium
or any neuromuscular blocking agent is contemplated
in
the ICU, it is recommended that neuromuscular transmission be monitored
continuously during administration and recovery with the help of a
nerve
stimulator. Additional doses of vecuronium
or any
other neuromuscular blocking agent should not be
given
before there is a definite response to T1 or to the first twitch. If no
response is elicited, infusion
administration should
be discontinued until a response returns.
Train
of Four is the test used to measure the degree of neuromuscular
blockade. A
peripheral nerve stimulator is used.
Count
the number of twitches the patient had out of four (0/4, 1/4, 2/4, 3/4,
4/4.)
Adjust the medication as ordered. Goal is 1/4 to 2/4 twitches.